Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1954 1
1955 2
1956 3
1957 2
1958 4
1960 2
1961 4
1962 2
1964 4
1965 4
1966 1
1967 1
1968 2
1969 2
1970 5
1972 9
1973 7
1974 4
1975 10
1976 9
1977 6
1978 6
1979 8
1980 9
1981 15
1982 16
1983 15
1984 18
1985 13
1986 14
1987 20
1988 25
1989 19
1990 27
1991 24
1992 30
1993 30
1994 30
1995 42
1996 39
1997 31
1998 42
1999 42
2000 51
2001 59
2002 72
2003 59
2004 70
2005 91
2006 86
2007 97
2008 173
2009 184
2010 186
2011 248
2012 219
2013 194
2014 171
2015 183
2016 188
2017 182
2018 173
2019 200
2020 233
2021 232
2022 225
2023 219
2024 94

Text availability

Article attribute

Article type

Publication date

Search Results

4,072 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Iudith-Anci
Page 1
Did you mean judith anti ki (3 results)?
Poly[dipotassium [(mu(6)-2,2',2'',2'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis-(methyl-ene)]tetra-kis-(sulfanedi-yl)}tetra-acetato)-disilver(I)] 5.2-hydrate].
Pacifico J, Stoeckli-Evans H. Pacifico J, et al. IUCrdata. 2022 Feb 1;7(Pt 2):x220077. doi: 10.1107/S2414314622000773. eCollection 2022 Feb. IUCrdata. 2022. PMID: 36340876 Free PMC article.
The reaction of AgNO(3) with the ligand 2,2',2'',2'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis-(methyl-ene)]tetra-kis-(sulfanedi-yl)}tetra-acetic acid in the presence of a potassium acetate buffer lead to the formation of a silver(I)-potassium-organic framework, poly[di …
The reaction of AgNO(3) with the ligand 2,2',2'',2'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis-(methyl-ene)]tetra-kis-(sulfanedi-y …
Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms.
Bernsen EC, Hogenes VJ, Nuijen B, Hanff LM, Huitema ADR, Diekstra MHM. Bernsen EC, et al. Pharmaceutics. 2022 Dec 17;14(12):2834. doi: 10.3390/pharmaceutics14122834. Pharmaceutics. 2022. PMID: 36559327 Free PMC article. Review.
Over 75 kinase inhibitors (KIs) have been approved for the treatment of various cancers. KIs are orally administrated but mostly lack pediatric age-appropriate dosage forms or instructions for dose manipulation. ...Therefore, the goals of this review were to provide …
Over 75 kinase inhibitors (KIs) have been approved for the treatment of various cancers. KIs are orally administrated but most …
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications.
Potter AS, Hulsurkar MM, Wu L, Narasimhan B, Karimzad K, Koutroumpakis E, Palaskas N, Deswal A, Kantharia BK, Wehrens XHT. Potter AS, et al. JACC Clin Electrophysiol. 2023 Apr;9(4):591-602. doi: 10.1016/j.jacep.2022.11.034. Epub 2023 Feb 22. JACC Clin Electrophysiol. 2023. PMID: 37100538 Free article. Review.
Within this broad category of targeted therapies is the class of kinase inhibitors (KIs), which target kinases that have undergone aberrant activation in cancerous cells. ...Furthermore, there are unique considerations to treating KI-induced AF because of the anticoagulant …
Within this broad category of targeted therapies is the class of kinase inhibitors (KIs), which target kinases that have undergone ab …
(mu-2,2',2'',2'''-{[Pyrazine-2,3,5,6-tetra-yltetra-kis(methyl-ene)]tetra-kis(sulfanedi-yl)}tetra-acetato)bis-[aqua-nickel(II)] hepta-hydrate.
Pacifico J, Stoeckli-Evans H. Pacifico J, et al. IUCrdata. 2021 Dec 9;6(Pt 12):x211295. doi: 10.1107/S2414314621012955. eCollection 2021 Dec. IUCrdata. 2021. PMID: 36337591 Free PMC article.
Reaction of the ligand 2,2',2'',2'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis-(methyl-ene)]tetra-kis-(sulfanedi-yl)}tetra-acetic acid (H(4)L1), with NiCl(2) leads to the formation of a binuclear complex, (mu-2,2',2'',2'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis-(met …
Reaction of the ligand 2,2',2'',2'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis-(methyl-ene)]tetra-kis-(sulfanedi-yl)}tetra-acetic a …
Web support for the more efficient discovery of kinase inhibitors.
Chen Y, Wang ZZ, Hao GF, Song BA. Chen Y, et al. Drug Discov Today. 2022 Aug;27(8):2216-2225. doi: 10.1016/j.drudis.2022.04.002. Epub 2022 Apr 7. Drug Discov Today. 2022. PMID: 35398561 Review.
Kinases have a crucial role in cell signaling and are important drug targets, given that aberrant kinase activity has been linked to most disease areas. Therefore, kinase inhibitors (KIs) have significant potential as new therapeutics. In recent years, an increasing amount …
Kinases have a crucial role in cell signaling and are important drug targets, given that aberrant kinase activity has been linked to most di …
Synergizing immunotherapy with molecular-targeted anticancer treatment.
Fernández A. Fernández A. Drug Discov Today. 2014 Sep;19(9):1427-32. doi: 10.1016/j.drudis.2014.03.022. Epub 2014 Mar 28. Drug Discov Today. 2014. PMID: 24685718 Review.
The therapeutic opportunity for anticancer kinase inhibitors (KIs) that block cell-signaling pathways is materializing. Yet, these molecular-targeted therapies are not tailored to be allies of the immune system, and often antagonize it despite generating antigenic activity …
The therapeutic opportunity for anticancer kinase inhibitors (KIs) that block cell-signaling pathways is materializing. Yet, these mo …
Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer.
Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, Püsküllüoğlu M. Grela-Wojewoda A, et al. Int J Mol Sci. 2022 Mar 4;23(5):2815. doi: 10.3390/ijms23052815. Int J Mol Sci. 2022. PMID: 35269958 Free PMC article. Review.
Kinase inhibitors (KIs) represent a growing class of drugs directed at various protein kinases and used in the treatment of both solid tumors and hematologic malignancies. ...The guidelines for cardiac monitoring and management of the most common cardiotoxic effects of pro …
Kinase inhibitors (KIs) represent a growing class of drugs directed at various protein kinases and used in the treatment of both soli …
Coumarins effectively inhibit bacterial α-carbonic anhydrases.
Giovannuzzi S, Hewitt CS, Nocentini A, Capasso C, Flaherty DP, Supuran CT. Giovannuzzi S, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):333-338. doi: 10.1080/14756366.2021.2012174. J Enzyme Inhib Med Chem. 2022. PMID: 34979838 Free PMC article.
Fluorescent kinase inhibitors as probes in cancer.
Usama SM , Zhao B , Burgess K . Usama SM , et al. Chem Soc Rev. 2021 Sep 7;50(17):9794-9816. doi: 10.1039/d1cs00017a. Epub 2021 Jul 22. Chem Soc Rev. 2021. PMID: 34291273 Free PMC article. Review.
Fluorescent dyes attached to kinase inhibitors (KIs) can be used to probe kinases in vitro, in cells, and in vivo. ...
Fluorescent dyes attached to kinase inhibitors (KIs) can be used to probe kinases in vitro, in cells, and in vivo. ...
Béla Lombay (1942-2023).
Kis É. Kis É. Pediatr Radiol. 2023 Sep;53(10):2163-2164. doi: 10.1007/s00247-023-05743-1. Epub 2023 Aug 15. Pediatr Radiol. 2023. PMID: 37580536 No abstract available.
4,072 results